InflaRx (NASDAQ:IFRX) Releases Earnings Results, Beats Expectations By $0.18 EPS

InflaRx (NASDAQ:IFRX) issued its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.18, Zacks reports. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%.

InflaRx Stock Up 1.6 %

NASDAQ IFRX opened at $1.28 on Friday. The stock’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.90. InflaRx has a twelve month low of $1.13 and a twelve month high of $2.82. The company has a market capitalization of $85.93 million, a price-to-earnings ratio of -1.19 and a beta of 1.98.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of InflaRx in a report on Friday.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.